Navigation Links
Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
Date:2/17/2011

SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has been shown to reduce and/or block HCV infection in in vitro preclinical models and more recently, has displayed the potential to amplify the effectiveness of existing therapies in difficult to treat HCV-infected patients. This is in addition to CTS-1027's anti-inflammatory and anti-fibrotic effects which have been well established in models of acute hepatitis and liver fibrosis.

"Our previous clinical trials indicate that CTS-1027 used in combination with existing standard-of-care HCV drugs has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by new uninfected liver cells. While reducing HCV virus production in infected cells is extremely important, eliminating HCV-infected cells is crucial to curing HCV," said Dr. Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in combination with the existing standard-of-care drugs as well as the new antiviral drugs under development."

"We have established a collaborative relationship with key opinion leaders and clinical investigators in the hepatitis community," said Ms. MiRa Huyghe, Vice President of Clinical Devel
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
2. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
3. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
7. Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
8. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 Par Pharmaceutical Companies, Inc. ... on Friday, August 7, 2015 at 9:00 a.m. EDT ... quarter ended June 30, 2015.  Par is privately held ... public in its filings with the Securities and Exchange ... its website by following the instructions at http://www.parpharm.com/financialinfo ...
(Date:8/3/2015)... 3, 2015 Ortho Clinical Diagnostics (OCD) today ... Chief Corporate Brand and Communications Officer, effective immediately. As ... Bouryal will lead the company,s worldwide corporate brand and ... to an independent company by adding sites in countries ... Chief Executive Officer Dr. Martin Madaus . ...
(Date:8/3/2015)... 2015 According to a ... "Global Market Study on Physiotherapy Equipment - ... by 2022", the global physiotherapy equipment market is estimated to ... 2015 and is expected to grow at a ... account for US$23.7 Bn by 2022. View ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... TROY, Mich., Oct. 25, 2011 CareTech Solutions, an ... for over 180 U.S. hospitals announced today that the ... information officer, Detroit Medical Center (DMC), Vanguard Health System ... the 2011 College of Health Information Management Executives (CHIME) ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the ... today the contractual agreements for S1P1 lead compounds, AMG ... a sealed bid sale.   AMG-369, AMG-277 ... as part of License Agreement between Amgen and Epix ...
Cached Medicine Technology:Detroit Medical Center Shares Smart Room Case Study at CHIME 2011 Fall CIO Forum 2Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that ... care costs. , Annually, more than 8.6 million adverse drug events are ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... ... , ... The U.S. Food and Drug Administration (FDA) recently approved a new ... which occurs naturally in the body and helps absorb and breakdown fat cells. Previously, ... body. These are invasive procedures and very expensive for most people. Now with Kybella, ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... researchers from Stanford have identified the nitric oxide gas as ... resulting in the development of an embryo.He says,it begins with ... ,The research is based on the sex lives of ... in the Pacific Ocean just a few yards from Epel's ...
... flowing smoothly after angioplasty shows surprising success in early testing. ... the drug-coated stent. //In testing on 50 patients over 3 ... ,More than 2 million Americans undergo angioplasty annually, ... most of them if these promising results hold up in ...
... in arresting the dental plaque bacteria believed to be ... report at the American Association// for Dental Research annual ... produces hydrogen peroxide is the key to the antimicrobial ... associate professor of biochemistry at the University of Waikato, ...
... Scientists form Johns Hopkins University School of Medicine have recently ... in the brain that lets us stop smelling something, even ... in a recent issue of the journal Science show that ... receptor cells.The main job of these neurons is to detect ...
... Corp is close to signing a deal to acquire the ... fellow US drugmaker Abbott Laboratories Inc. An industry source who ... in the next few days to buy the stake in ... senior Abbott officials from the company’s regional office in singapore ...
... undergoing open heart surgery for patients in their mid-eighties ... and advisable for the elderly.// ,According to Dr. ... University ,open heart surgery, if indicated, is safe and ... and head of cardiac surgery at Southeastern Healthcare in ...
Cached Medicine News:Health News:The route to fertilization, 2Health News:Heart Surgery Is Getting Safer for the Old 2
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... Catheter with Accutrol is similar in design ... that it incorporates a temperature probe at ... temperature probe can accurately determine the patient's ... provides temperature accuracy comparable to a pulmonary ...
... These markers are available with 16 or 24 ... 6.5mm diameter, and an outer 9.5mm diameter. The markers ... in one single step for a 16 or 24 ... outer points on the cornea to achieve a precise ...
... Through A 1.0mm Incision., ,Special Direct Acting ... Improved ... Approach., ,Recessed Jaws For Improved Sub-Incisional Flap ... Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed For ...
Medicine Products: